KMTS logo

Kestra Medical Technologies, Ltd. Stock Price

NasdaqGS:KMTS Community·US$1.4b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 1 Fair Values set on narratives written by author

KMTS Share Price Performance

US$22.24
5.21 (30.59%)
US$29.14
Fair Value
US$22.24
5.21 (30.59%)
23.7% undervalued intrinsic discount
US$29.14
Fair Value
Price US$22.24
AnalystConsensusTarget US$29.14
AnalystHighTarget US$32.00
AnalystLowTarget US$18.74

KMTS Community Narratives

·
Fair Value US$29.14 23.7% undervalued intrinsic discount

Wearable Defibrillator Underpenetration Will Drive Long-Term Expansion In Cardiac Protection Adoption

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
·
Fair Value US$32 30.5% undervalued intrinsic discount

Wearable Cardiac Protection Tailwinds Will Drive Stronger Market Adoption Over The Next Decade

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
·
Fair Value US$18.74 18.7% overvalued intrinsic discount

Cardiac Recovery Catalysts Will Shape Guideline Adoption And Margin Progress Over The Long Term

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Trending Discussion

No trending discussion available.

Updated Narratives

KMTS logo

KMTS: Revenue Momentum And Clinical Data Will Support Bullish 2027 Outlook

Fair Value: US$32 30.5% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
KMTS logo

Cardiac Recovery Catalysts Will Shape Guideline Adoption And Margin Progress Over The Long Term

Fair Value: US$18.74 18.7% overvalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
KMTS logo

Wearable Defibrillator Underpenetration Will Drive Long-Term Expansion In Cardiac Protection Adoption

Fair Value: US$29.14 23.7% undervalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet with limited growth.

1 Risk
2 Rewards

Kestra Medical Technologies, Ltd. Key Details

US$95.1m

Revenue

US$46.3m

Cost of Revenue

US$48.9m

Gross Profit

US$180.5m

Other Expenses

-US$131.6m

Earnings

Last Reported Earnings
Apr 30, 2026
Next Reporting Earnings
n/a
-2.25
51.37%
-138.36%
16.4%
View Full Analysis

About KMTS

Founded
2014
Employees
443
CEO
Brian Webster
WebsiteView website
kestramedical.com

Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease through connected monitoring, therapeutic intervention, and data-driven clinical insights. The company also develops and commercializes Cardiac Recovery System platform, an integrated cardiac recovery ecosystem designed to support patients at elevated risk of sudden cardiac arrest (SCA) during vulnerable periods of recovery. Its platform provides ASSURE Wearable Cardioverter Defibrillator (WCD), which continuously monitors patient heart rhythms and automatically delivers defibrillation therapy when life-threatening ventricular arrhythmias are detected; digital patient engagement and clinical workflow solutions designed to improve patient adherence, support care coordination, and provide actionable clinical insights throughout the recovery process; and integrated platform generates continuous cardiac rhythm data and clinically actionable insights. Kestra Medical Technologies, Ltd. was founded in 2014 and is based in Kirkland, Washington.

Recent KMTS News & Updates

Narrative Update Jul 15

KMTS: Revenue Momentum And Clinical Data Will Support Bullish 2027 Outlook

Kestra Medical Technologies' analyst price target has shifted from $30 to $32, as analysts point to stronger Assure prescription volume growth, broader account adoption, improved revenue cycle management, and updated clinical and algorithm data that support the revised fair value and model assumptions. What's in the News Kestra Medical Technologies reported Q4 fiscal 2026 revenue of US$28.6 million, with full year revenue rising 59% and Q4 revenue up 66%, while gross margin reached 54.8% as the rental model scaled.

Recent updates

No updates